GERMANY - 2024/02/16: In this photo illustration, a Johnson & Johnson logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson (NYSE: JNJ) currently trades around $160 per share, 15% below its peak level of over $185 seen in April 2022, and it seems like it can see higher levels over time. JNJ stock was trading at around $180 in June 2022, just before the Fed started increasing rates, and ...

Johnson & Johnson (JNJ) closed at $156.76 in the latest trading session, marking a -0.9% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.63%. At the same time, the Dow added 0.2%, and the tech-heavy Nasdaq gained 0.82%.Heading into today, shares of the world's biggest maker of health care products had gained 1.04% over the past month, outpacing the Medical sector's gain of 0.91% and lagging the S&P 500's gain of 1.76% in that time.The upcoming earnings release of Jo ...

Johnson & Johnson on Monday announced it is working with Nvidia to develop and scale new artificial intelligence applications for surgery. J&J's MedTech unit and Nvidia plan to integrate AI within devices and platforms from pre-op to post-op to help ensure that surgeons have access to all the information they need, Nvidia's vice president of health care Kimberly Powell said. For instance, the companies are using AI to analyze surgical video and automate the time-consuming documentation required after a proc ...

Johnson & Johnson (JNJ) announced that an FDA committee has unanimously recommended expanded use of its multiple myeloma drug Carvykti for earlier lines of treatment.J&J is looking for expansion of Carvykti’s label to include treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and who are refractory to Bristol-Myers Squibb’s Revlimid (lenalidomide).The FDA’s O ...

Johnson & Johnson (JNJ -0.65%) is one of the leading and most recognizable names in healthcare. It generates billions in revenue and profit every year and its products are used all over the world. It's a truly global organization that has achieved considerable success over the years.It also pays a dividend that it has increased for decades, giving investors plenty of incentive to buy and hold the stock, simply collecting that recurring payout along the way.In the past 10 years, the stock's total returns (wh ...

Undervalued healthcare stocks are primed for a comeback this year, proving themselves as lucrative investments amidst a revitalized market. With a significant uptick in performance, the S&P 500 Health Care index soared roughly 7% year-to-date (YTD), marking a robust recovery from last year’s challenges. This resurgence underscores the sector’s resilience and adaptability post-pandemic.Elevating the allure of undervalued healthcare stocks, McKinsey & Company’s predictive analytics forecasts a compelling grow ...

Johnson & Johnson (NYSE:JNJ) Barclays 26th Annual Global Healthcare Conference March 13, 2024 10:45 AM ET Company Participants Peter Menziuso - Company Group Chairman, Johnson & Johnson Vision Conference Call Participants Matt Miksic - Barclays Matt Miksic Good morning, everybody. Thanks so much for joining us. I'm so pleased to have today Peter Menziuso. I like with a name like Peter, -- You think I'd be better at pronouncing complicated names. But a Company Group Chairman, Johnson & Johnson Vision, apprec ...

Johnson & Johnson (NYSE:JNJ) Leerink Partners Global Biopharma Conference March 12, 2024 1:00 PM ET Company Participants Joe Wolk - Chief Financial Officer Raychel Kruper - Senior Director of Investor Relations Conference Call Participants David Risinger - Leerink Partners David Risinger Okay. So, we're going to get started here. Sorry, we're starting two minutes late. My apologies. So, my name is Dave Risinger. If you don't know me, I cover diversified biopharmaceuticals for Leerink Partners. And it's very ...

Would you like a relatively safe way to boost the amount of passive income you have to work with after you retire? Try beginning your search with the 30 stocks that make up the Dow Jones Industrial Average.Income-seeking investors can be relatively confident about Dow stocks, because their underlying businesses must demonstrate profitability on a recurring basis before they're even considered for addition to the index. At recent prices, the average stock in the Dow Jones Industrial Average index offers a pa ...

Johnson & Johnson (JNJ) has announced the submission of a supplemental biologics license application (sBLA) seeking approval of its immunology medicine, Tremfya, for a new indication — moderately to severely active ulcerative colitis (UC).Tremfya is presently approved to treat certain patients with plaque psoriasis and active psoriatic arthritis in several countries, including the United States and the EU. The sBLA for the UC indication was based on data from the phase III QUASAR study. Data from this study ...